BRCA2 and ovarian cancer: Therefore, inhibition of WRN can enhance the cytotoxicity of PARP inhibitors (olaparib) in BRCA2-deficient ovarian cancer cells, suggesting that WRN may be used as an alternative or auxiliary target for PARP inhibitors [43].